Furthermore, the CCR5 RO assay correctly identified
Furthermore, the CCR5 RO assay correctly identified individuals treated with Leronlimab versus placebo following unblinding, as treated individuals presented at baseline with no CCR5 RO, but then achieved full CCR5 RO on peripheral blood CD4+ T cells at the two follow-up clinical visits, while placebo-treated participants never presented with CCR5 RO (Figure 5B).
In line with the preclinical macaque results, we observed increased frequencies of circulating CCR5+CD4+ T cells following Leronlimab dosing. After Leronlimab initiation, frequencies of CCR5+CD4+ T cells circulating in the peripheral blood in Leronlimab-treated participants were statistically higher than in untreated participants (Figure 5C). Thus, the longitudinal CD4+ T cell CCR5 RO in Leronlimab-treated participants and lack of
measurable CCR5 RO in Leronlimab-untreated participants demonstrates the robustness and sensitivity of the clinical CCR5 RO assay"
Tested against placebo & the companies you mentioned would too have their own Vs. placebo data
Do you think that would be the quickest A-B comparison for look @ how LL did against their placebo compsrisons
& if LL data showed a big difference of CD 4+ Vs theirs, then justification of going frwd further ??....would seem so
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Overview of the Pharmaceutical Contract Packaging Market The global market for pharmaceutical contract packaging is set to experience notable growth, propelled by advances in technology and increased investment in research and development. Estimates indicate a remarkable increase of USD 9.32 billion from 2024 to 2028, equating to a compound annual growth rate (CAGR) of...
Continue Reading
Palantir's CTO Discusses National Security Challenges Shyam Sankar, the Chief Technology Officer of the innovative data analytics and cybersecurity company Palantir Technologies Inc. (NASDAQ: PLTR), recently expressed serious concerns regarding America's fading deterrence capacity. While appearing on the New York Times podcast, he made it clear that the nation is no...
Continue Reading
Investigation Launch: A Call to Action for Shareholders Bragar Eagel & Squire, P.C., a highly regarded law firm focused on shareholder rights, is launching an investigation into potential claims against Super Micro Computer, Inc. (NASDAQ: SMCI). This examination primarily targets the company’s conduct leading up to a class action lawsuit filed against it. The firm is...
Continue Reading
Strong Performance in the Fourth Quarter The Children’s Place, Inc. (Nasdaq: PLCE), recognized as North America's leading children's specialty retailer, has reported remarkable progress in its financial performance for the fourth quarter. The company achieved net sales totaling $409 million for this quarter, along with a total of $1.386 billion for the entire fiscal...
Continue Reading
Understanding Extra Space Storage's Historical Returns Extra Space Storage (NYSE: EXR) has significantly outperformed the market during the past 15 years, registering an impressive annualized return of 16.14%. This performance is not just a statistic; it represents a compound growth that can transform an initial investment. The Power of Compound Returns To illustrate...
Continue Reading